AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit in reducing cardiovascular-related deaths. This setback caused AstraZeneca's stock to fall about 8% in London, reflecting investor disappointment. The failure raises questions about the future of this treatment and impacts both companies' market valuations.
ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, ...
Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, ...
Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary e...
SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors an...
The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also dec...
